KisoJi Biotechnology Secures $41 Million to Propel Antibody Development and AI Innovations KisoJi Biotechnology raises $41 million to advance its leading antibody program KJ-103 and enhance AI capabilities in development for key diseases.

KisoJi Biotechnology Secures $41 Million to Propel Antibody Development and AI Innovations #Canada #Montreal #KisoJi_Biotech #TROP2 #KJ-103